Search

Your search keyword '"Moulton, Brian"' showing total 231 results

Search Constraints

Start Over You searched for: Author "Moulton, Brian" Remove constraint Author: "Moulton, Brian"
231 results on '"Moulton, Brian"'

Search Results

1. Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients

2. Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer

3. Analysis of Cell-Free DNA to Predict Outcome to Bevacizumab Combination Therapy in Metastatic Colorectal Cancer Patients

4. Abstract 5584: Analysis of cell free DNA to predict outcome to Bevacizumab combination therapy in metastatic colorectal cancer patients

5. Abstract P1-11-09: Five year follow up of a randomized phase II comparison of neo-adjuvant docetaxel, carboplatin, trastuzumab with or without lapatinib in HER-2 positive breast cancer

17. From molecules to crystal engineering: supramolecular isomerism and polymorphism in network solids

18. Abstract CT212: A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)

27. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

29. Additional file 2: Table S2. of Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

30. Single-molecule magnets: a family of [Mn.sup.III]/[Ce.sup.IV] complexes with a [[Mn.sub.8]Ce[O.sub.8]](12+) core

31. Employment of 2,6-diacetylpyridine dioxime as a new route to high nuclearity metal clusters: [Mn.sub.6] and [Mn.sub.8] complexes

32. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

33. Temporal patterns of late bowel and bladder radiotherapy toxicity in a randomised controlled trial assessing duration of neo-adjuvant hormones in prostate cancer

34. Template synthesis and single-molecule magnetism properties of a complex with spin S= 16 and a [MN8O8](super 8+) saddle-like core

35. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids

36. Supramolecular isomerism in coordination compounds: Nanoscale molecular hexagons and chains

40. Phase II clinical trial of first or second-line treatment with Bortezomib in patients with malignant pleural mesothelioma

41. ICORG 06-41: A phase II trial of single-agent sorafenib in the treatment of platinum-pretreated relapsed gastroesophageal adenocarcinoma (GECa).

44. Correction for Polymorphs, Salts and Cocrystals: What’s in a Name?

46. Polymorphs, Salts, and Cocrystals: What’s in a Name?

47. Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

49. Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.

Catalog

Books, media, physical & digital resources